ArticlePloS one2013
Corporate philanthropy, political influence, and health policy.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Content Analysis of the Corporate Social Responsibility Practices of 9 Major Cannabis Companies in Canada and the US.JAMA network open · 2022Pooled it
- "Favoring those who contributed to their political campaigns": an analysis of the incentives received by the food industry in Colombia in the period of 2018-2020.Globalization and health · 2025Article
- Building a Systems Map: Applying Systems Thinking to Unhealthy Commodity Industry Influence on Public Health Policy.International journal of health policy and management · 2024Article
- Typology of how 'harmful commodity industries' interact with local governments in England: a critical interpretive synthesis.BMJ global health · 2023Article
- Corporate Political Activity: Taxonomies and Model of Corporate Influence on Public Policy.International journal of health policy and management · 2023Article
- Combatting tobacco industry lobbyists in public health.Tobacco induced diseases · 2023Article
- National Public Health Surveillance of Corporations in Key Unhealthy Commodity Industries - A Scoping Review and Framework Synthesis.International journal of health policy and management · 2023Article
- Article
- 'As Long as It Comes off as a Cigarette Ad, Not a Civil Rights Message': Gender, Inequality and the Commercial Determinants of Health.International journal of environmental research and public health · 2020Review
- Article
- Impact of the WHO FCTC over the first decade: a global evidence review prepared for the Impact Assessment Expert Group.Tobacco control · 2019Review
- Public Meets Private: Conversations Between Coca-Cola and the CDC.The Milbank quarterly · 2019Article
- United Nations Global Compact: an 'Inroad' into the UN and reputation boost for the tobacco industry.Tobacco control · 2018Article
- US Media Coverage of Tobacco Industry Corporate Social Responsibility Initiatives.Journal of community health · 2018Article
- African media coverage of tobacco industry corporate social responsibility initiatives.Global public health · 2018Article
- Article
- Environmental impacts of tobacco product waste: International and Australian policy responses.Ambio · 2017Review
- Controlling corporate influence in health policy making? An assessment of the implementation of article 5.3 of the World Health Organization framework convention on tobacco control.Globalization and health · 2017Article
- Japan Tobacco International: To 'be the most successful and respected tobacco company in the world'.Global public health · 2017Article
- Social determinants of tobacco use: towards an equity lens approach.Tobacco prevention & cessation · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundThe Framework Convention of Tobacco Control (FCTC) provides a basis for nation states to limit the political effects of tobacco industry philanthropy, yet progress in this area is limited. This paper aims to integrate the findings of previous studies on tobacco industry philanthropy with a new analysis of British American Tobacco's (BAT) record of charitable giving to develop a general model of corporate political philanthropy that can be used to facilitate implementation of the FCTC.
methodAnalysis of previously confidential industry documents, BAT social and stakeholder dialogue reports, and existing tobacco industry document studies on philanthropy.
resultsThe analysis identified six broad ways in which tobacco companies have used philanthropy politically: developing constituencies to build support for policy positions and generate third party advocacy; weakening opposing political constituencies; facilitating access and building relationships with policymakers; creating direct leverage with policymakers by providing financial subsidies to specific projects; enhancing the donor's status as a source of credible information; and shaping the tobacco control agenda by shifting thinking on the importance of regulating the market environment for tobacco and the relative risks of smoking for population health. Contemporary BAT social and stakeholder reports contain numerous examples of charitable donations that are likely to be designed to shape the tobacco control agenda, secure access and build constituencies. CONCLUSIONS AND RECOMMENDATIONS: Tobacco companies' political use of charitable donations underlines the need for tobacco industry philanthropy to be restricted via full implementation of Articles 5.3 and 13 of the FCTC. The model of tobacco industry philanthropy developed in this study can be used by public health advocates to press for implementation of the FCTC and provides a basis for analysing the political effects of charitable giving in other industry sectors which have an impact on public health such as alcohol and food.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.